GCM Grosvenor Holdings LLC Decreases Holdings in Natera, Inc. (NASDAQ:NTRA)

GCM Grosvenor Holdings LLC decreased its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 35.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 85,356 shares of the medical research company's stock after selling 47,544 shares during the quarter. Natera comprises about 2.0% of GCM Grosvenor Holdings LLC's portfolio, making the stock its 13th largest holding. GCM Grosvenor Holdings LLC owned approximately 0.06% of Natera worth $13,512,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of NTRA. Blue Trust Inc. lifted its stake in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after buying an additional 97 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after purchasing an additional 261 shares in the last quarter. Principal Securities Inc. lifted its holdings in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares during the period. Steward Partners Investment Advisory LLC raised its holdings in Natera by 1,328.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after buying an additional 332 shares during the period. Finally, Global Retirement Partners LLC raised its stake in shares of Natera by 55.0% during the fourth quarter. Global Retirement Partners LLC now owns 434 shares of the medical research company's stock valued at $69,000 after purchasing an additional 154 shares during the period. Institutional investors own 99.90% of the company's stock.

Insider Transactions at Natera

In related news, insider Solomon Moshkevich sold 6,000 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total transaction of $859,740.00. Following the completion of the transaction, the insider now owns 143,768 shares in the company, valued at approximately $20,600,516.72. This represents a 4.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gail Boxer Marcus sold 4,000 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $151.61, for a total transaction of $606,440.00. Following the completion of the transaction, the director now directly owns 9,704 shares in the company, valued at $1,471,223.44. The trade was a 29.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 152,436 shares of company stock valued at $22,019,079. Company insiders own 7.60% of the company's stock.

Natera Stock Up 3.5%

Shares of NASDAQ:NTRA traded up $5.34 during midday trading on Monday, hitting $157.29. 1,935,423 shares of the company's stock traded hands, compared to its average volume of 1,388,529. Natera, Inc. has a twelve month low of $92.14 and a twelve month high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company has a market cap of $21.26 billion, a PE ratio of -89.37 and a beta of 1.79. The firm's fifty day moving average price is $147.70 and its two-hundred day moving average price is $156.18.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The company had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business's revenue for the quarter was up 36.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.56) EPS. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on NTRA shares. Royal Bank of Canada assumed coverage on shares of Natera in a research note on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective on the stock. Robert W. Baird upped their target price on Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Piper Sandler increased their target price on Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 price target on shares of Natera in a research report on Wednesday, February 26th. Finally, Barclays boosted their price target on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Natera presently has a consensus rating of "Moderate Buy" and a consensus target price of $181.82.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.